Assessment of the pharmacokinetic profile of novel s-triazine derivatives and their potential use in treatment of Alzheimer's disease
详细信息 查看全文
- 作者：Jovana Trifunović ; jovanatrifunovic@gmx.com ; jovanatrifunovic@uns.ac.rs ; Vladan Borčić ; Sa&scaron ; a Vukmirović ; Momir Mikov
- 关键词：Alzheimer's disease ; s-Triazine ; Lipophilicity ; Molecular docking ; QSAR
- 刊名：Life Sciences
- 出版年：2017
- 出版时间：1 January 2017
- 年：2017
- 卷：168
- 期：Complete
- 页码：1-6
- 全文大小：1063 K
- 卷排序：168
文摘
The current treatment of Alzheimer's disease is purely symptomatic. Scientists are looking for new treatment options which could alter the course of the disease and improve the quality of life in patients with Alzheimer's disease. In this paper 14 novel s-triazine molecules have been evaluated for their lipophilicity. In addition docking study was carried out to evaluate acetylcholinesterase activity of these compounds.Main methodsLipophilicity was evaluated by RP HPTLC using 5 different mobile phases and obtained results were used in calculations of pharmacokinetic parameters - logBB, Ka and Pej. Multiple linear regression analysis was refined, taking account of molecular polarity (total polar surface area, TPSA) and molecular weight (Mw) descriptors. Appropriate QSAR models were developed. Docking studies were carried out using the Vina docking.Key findingsFive out of fourteen compounds evaluated [5-10] are selected as the most promising compounds with satisfactory pharmacokinetic properties and good docking scores.SignificanceCompound 10 possesses the best combination of favourable pharmacokinetic characteristics (brain penetration, intestinal absorption) and capacity for acetylcholinesterase inhibition. Consequently this molecule should be further evaluated for potential therapeutic use in Alzheimer's disease.